India, June 3 -- TG Therapeutics, Inc. (TGTX) shares rose 10.48 percent, gaining $3.84 to $40.48 on Tuesday after the company reported positive pharmacokinetic, pharmacodynamic, safety, and tolerability results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI compared with the currently approved intravenous version.
The stock is currently trading at $40.48, compared with its previous close of $36.64. During the session, it opened at $38.65 and traded between $37.96 and $40.69. Trading volume reached 1.02 million shares.
The company said the proprietary high-concentration, low-volume formulation was well tolerated and achieved sustained drug exposure. Data from the study support the quarterly and every-other...